Announcement • Mar 05
Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 28, 2026 Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 28, 2026, at 12:00 Egypt Standard Time. Location: cairo Egypt Reported Earnings • May 16
First quarter 2025 earnings released First quarter 2025 results: Revenue: ج.م2.30b (up 53% from 1Q 2024). Net income: ج.م318.6m (down 47% from 1Q 2024). Profit margin: 14% (down from 40% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Africa. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year. Board Change • May 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Mar 05
Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 26, 2025 Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 26, 2025, at 14:00 Egypt Standard Time. Location: cairo Egypt Reported Earnings • Nov 16
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: ج.م2.07b (up 47% from 3Q 2023). Net income: ج.م204.9m (up 52% from 3Q 2023). Profit margin: 9.9% (in line with 3Q 2023). Price Target Changed • Nov 14
Price target increased by 15% to ج.م69.46 Up from ج.م60.53, the current price target is an average from 3 analysts. New target price is 44% above last closing price of ج.م48.11. Stock is up 27% over the past year. The company posted earnings per share of ج.م5.53 last year. Reported Earnings • Aug 17
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: ج.م1.88b (up 47% from 2Q 2023). Net income: ج.م175.6m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Africa. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Aug 04
Now 21% undervalued Over the last 90 days, the stock has risen 5.2% to ج.م37.85. The fair value is estimated to be ج.م48.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 29% in a year. Earnings are forecast to decline by 25% in the next year. Announcement • Aug 01
Egyptian International Pharmaceutical Industries Company(CASE:PHAR) dropped from EGX 30 Index Egyptian International Pharmaceutical Industries Company has been dropped from EGX 30 Index. Valuation Update With 7 Day Price Move • May 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ج.م35.00, the stock trades at a trailing P/E ratio of 6.3x. Average forward P/E is 12x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م38.38 per share. Upcoming Dividend • Apr 24
Upcoming dividend of ج.م2.00 per share Eligible shareholders must have bought the stock before 28 April 2024. Payment date: 29 August 2024. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (6.8%). Lower than average of industry peers (3.0%). Declared Dividend • Apr 10
Dividend of ج.م2.00 announced Shareholders will receive a dividend of ج.م2.00. Ex-date: 25th April 2024 Payment date: 29th August 2024 Dividend yield will be 4.6%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 3.5% over the last 3 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Mar 20
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to ج.م49.35. The fair value is estimated to be ج.م40.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 8.8%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 32% in the next 2 years. Buy Or Sell Opportunity • Mar 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to ج.م49.00. The fair value is estimated to be ج.م40.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 19% in the next 2 years. Price Target Changed • Feb 29
Price target increased by 19% to ج.م72.20 Up from ج.م60.53, the current price target is an average from 3 analysts. New target price is 47% above last closing price of ج.م49.20. Stock is up 40% over the past year. The company posted earnings per share of ج.م6.48 last year. New Risk • Nov 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 50% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 1.7% per year over the past 5 years. High level of non-cash earnings (50% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (50% increase in shares outstanding). Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ج.م32.81, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 15x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 17% over the past three years. New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 6.3% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (ج.م2.64b market cap, or US$85.3m). Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ج.م26.36, the stock trades at a trailing P/E ratio of 4.1x. Average forward P/E is 18x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 29% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م32.16 per share. Reported Earnings • Apr 08
Full year 2022 earnings released Full year 2022 results: Revenue: ج.م3.96b (up 15% from FY 2021). Net income: ج.م643.0m (up 23% from FY 2021). Profit margin: 16% (up from 15% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Africa. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ج.م34.71, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 18x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م34.36 per share. Price Target Changed • Nov 25
Price target decreased to ج.م63.87 Down from ج.م71.53, the current price target is an average from 3 analysts. New target price is 99% above last closing price of ج.م32.12. Stock is down 15% over the past year. The company posted earnings per share of ج.م5.27 last year. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 13
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: ج.م834.7m (up 8.3% from 2Q 2021). Net income: ج.م118.2m (up 28% from 2Q 2021). Profit margin: 14% (up from 12% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 12% growth forecast for the industry in Egypt. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 12
Third quarter 2021 earnings released The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ج.م899.3m (up 27% from 3Q 2020). Net income: ج.م87.8m (up 14% from 3Q 2020). Profit margin: 9.8% (down from 11% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 14
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ج.م770.9m (up 12% from 2Q 2020). Net income: ج.م92.5m (up 325% from 2Q 2020). Profit margin: 12% (up from 3.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Apr 18
Inaugural dividend of ج.م2.95 per share Eligible shareholders must have bought the stock before 25 April 2021. Payment date: 28 April 2021. The company last paid an ordinary dividend in March 2018. The average dividend yield among industry peers is 4.3%. Price Target Changed • Mar 25
Price target decreased to ج.م64.07 Down from ج.م68.90, the current price target is an average from 3 analysts. New target price is 49% above last closing price of ج.م43.12. Stock is down 26% over the past year. Is New 90 Day High Low • Jan 18
New 90-day low: ج.م42.53 The company is down 10.0% from its price of ج.م47.00 on 20 October 2020. The Egyptian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م36.24 per share. Analyst Estimate Surprise Post Earnings • Nov 18
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 2.8%. Over the next year, revenue is forecast to grow 14%, compared to a 7.5% growth forecast for the Pharmaceuticals industry in Egypt. Is New 90 Day High Low • Nov 16
New 90-day high: ج.م48.51 The company is up 2.0% from its price of ج.م47.60 on 18 August 2020. The Egyptian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م31.61 per share. Is New 90 Day High Low • Sep 30
New 90-day low: ج.م45.00 The company is down 15% from its price of ج.م52.90 on 30 June 2020. The Egyptian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م31.61 per share.